24.59
1.15 (4.91%)
| Previous Close | 23.44 |
| Open | 23.33 |
| Volume | 255,731 |
| Avg. Volume (3M) | 331,874 |
| Market Cap | 6,710,586,880 |
| Price / Earnings (TTM) | 46.40 |
| Price / Earnings (Forward) | 37.88 |
| Price / Sales | 4.83 |
| Price / Book | 3.96 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2025 |
| TTM Dividend Yield | 0.21% |
| Profit Margin | 11.16% |
| Operating Margin (TTM) | 13.97% |
| Diluted EPS (TTM) | 0.540 |
| Quarterly Revenue Growth (YOY) | 8.70% |
| Quarterly Earnings Growth (YOY) | 40.90% |
| Total Debt/Equity (MRQ) | 27.86% |
| Current Ratio (MRQ) | 1.83 |
| Operating Cash Flow (TTM) | 184.02 M |
| Levered Free Cash Flow (TTM) | -113.47 M |
| Return on Assets (TTM) | 4.88% |
| Return on Equity (TTM) | 9.14% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
| Medical Instruments & Supplies (Global) | Bearish | Bearish | |
| Stock | Stevanato Group S.p.A. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 0.83 |
|
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Growth |
| % Held by Insiders | 1.68% |
| % Held by Institutions | 112.67% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tri Locum Partners Lp | 31 Dec 2024 | 1,121,804 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Aug 2025 | Announcement | Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025 |
| 23 Jul 2025 | Announcement | Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S. |
| 22 Jul 2025 | Announcement | Stevanato Group to Report Second Quarter 2025 Financial Results on August 5, 2025 |
| TTM Dividend Yield | 0.21% |
| 3Y Average Dividend Yield | 0.26% |
| Payout Ratio | 11.52% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 04 Jun 2024 | 10 Apr 2024 | 15 Jul 2024 | 0.0573 Cash |
| 07 Jun 2023 | 05 Apr 2023 | 17 Jul 2023 | 0.0577 Cash |
| 13 Jun 2022 | 11 Apr 2022 | 13 Jul 2022 | 0.0546 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2024 | 0.057 | 1 | 0.26 |
| 2023 | 0.058 | 1 | 0.21 |
| 2022 | 0.055 | 1 | 0.30 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |